WO2019072045A1 - 一种cd169高亲和力抗肿瘤化合物及其制备方法和应用 - Google Patents
一种cd169高亲和力抗肿瘤化合物及其制备方法和应用 Download PDFInfo
- Publication number
- WO2019072045A1 WO2019072045A1 PCT/CN2018/103238 CN2018103238W WO2019072045A1 WO 2019072045 A1 WO2019072045 A1 WO 2019072045A1 CN 2018103238 W CN2018103238 W CN 2018103238W WO 2019072045 A1 WO2019072045 A1 WO 2019072045A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mixture
- tumor
- high affinity
- tcc
- solvent
- Prior art date
Links
- 0 C*(C)C(CC1*)(O)OC(C(C(*)C*)O)[C@]1N Chemical compound C*(C)C(CC1*)(O)OC(C(C(*)C*)O)[C@]1N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the invention relates to antitumor compounds, in particular to a CD169 high affinity antitumor compound and a preparation method and application thereof.
- Tumors are an important issue that threatens human health.
- various methods have been studied for tumor killing and anti-tumor drugs and methods.
- various chemotherapeutic drugs developed using the characteristics of tumor metabolism higher than normal tissues; monoclonal antibodies using tumor surface specific markers, such as Herceptin.
- monoclonal antibodies using tumor surface specific markers, such as Herceptin.
- people have begun to use the immune checkpoint inhibitors of the body's own immune system to conduct anti-tumor research, such as targeting various antibodies and small molecule inhibitors of PD1 and PDL-1. The research has achieved great results and is an important direction for anti-tumor in the future.
- Macrophages play an important role in the body's immune system. Macrophages not only directly phagocytose tumor cells, but also transmit fragments of phagocytic tumor cells to other immune cells, activate the body's own immune system, and carry out anti-tumor responses.
- SIGLEC Sialic acid-binding immunoglobulin-type lectins
- SIGLEC-1 also known as CD169
- SIGLEC-1 is mainly distributed on the surface of macrophages.
- SIGLEC1 is highly homologous in mouse and human, and therefore specifically binds to the N-acetylneuraminic acid trisaccharide sequence (Neu5Ac ⁇ 2-3Gal ⁇ 1-4GlcNAc), wherein Neu5AC stands for N-acetylneuraminic acid and Gal stands for half Lactose, GlcNAc stands for N-acetylglucosamine, and ⁇ 2-3 and ⁇ 1-4 are chemical bond linkages.
- N-acetylneuraminic acid trisaccharide sequence (Neu5Ac ⁇ 2-3Gal ⁇ 1-4GlcNAc)
- Neu5AC stands for N-acetylneuraminic acid and Gal stands for half Lactose
- GlcNAc stands for N-acetylglucosamine
- ⁇ 2-3 and ⁇ 1-4 are chemical bond linkages.
- SIGLEC1 binds to natural sialic acid sugar ligands with low affinity.
- the present invention provides a CD169 high affinity antitumor compound comprising the chemical formula:
- the invention also provides a preparation method of CD169 high affinity antitumor compound, comprising the following preparation steps:
- Step 1 mixing TCC Sia methyl ester, methanol and NaOH solution, and stirring at room temperature for a period of time to obtain a mixture M11;
- Step 2 in the mixture M11 obtained in step 1, adding HCl aqueous solution, adjusting the pH of the mixture M11 to 7, to obtain a mixture M12;
- Step 3 The mixture M12 obtained in the second step is subjected to solvent removal, and the residue after removing the solvent is purified to obtain a CD169 high affinity antitumor compound.
- the method for preparing the TCC Sia methyl ester in the first step comprises the following steps:
- EtOAc:MeOH 20:1 used in column chromatography in S230.
- EtOAc:MeOH 20:1 used for column chromatography in S370.
- the invention also provides the use of a CD169 high affinity anti-tumor compound as described above, for the treatment of a tumor.
- the invention provides a CD169 high affinity antitumor compound and a preparation and application thereof, wherein the CD169 high affinity antitumor compound is a 9-benzopyranthiophenanyl N-acetylneuraminic acid monosaccharide (TCC-Neu5Ac),
- TCC-Neu5Ac 9-benzopyranthiophenanyl N-acetylneuraminic acid monosaccharide
- a substance is a small molecule anti-tumor compound that can be used for tumor killing using its specific, broad-spectrum properties.
- the mechanism is that TCC-Neu5Ac can target tumors in vivo and metabolize and grow on the surface of tumor cells to form TCC-Neu5Ac ligand.
- the CD169 high affinity antitumor compound provided by the present invention is effective against various tumors and has an inhibitory effect on tumor metastasis.
- the CD169 high-affinity anti-tumor compound provided by the invention can not only be injected, but also exerts oral action, and has low cytotoxicity and animal toxicity, and has broad application prospect and market value.
- FIG. 1 is a distribution image of a CD169 high affinity antitumor compound provided in a human malignant glioma cell according to the present invention
- FIG. 2 is a distribution image of a CD169 high affinity antitumor compound provided in a mouse-derived melanoma cell according to the present invention
- FIG. 3 is a distribution analysis image of a CD169 high affinity antitumor compound provided in a mouse-derived melanoma cell according to the present invention.
- FIG. 4 is a graph showing the cell survival rate of a CD169 high affinity antitumor compound provided by the present invention.
- Figure 5 is a graph showing the effect of macrophages on the phagocytosis effect of tumor cells incubated with the CD169 high affinity antitumor compound provided by the present invention
- FIG. 6 is a photograph showing the appearance of a tumor-bearing mouse in which the experimental group 1 was injected with the CD169 high-affinity antitumor compound provided by the present invention
- Figure 7 is a photograph showing the appearance of a tumor-bearing mouse in a control group 1 injected with a PBS solution containing natural sialic acid;
- Figure 8 is a comparison of tumor size taken from mice of Experimental Group 1 and Control Group 1;
- Figure 9 is a comparative analysis of tumor size data taken from mice of Experimental Group 1 and Control Group 1;
- Figure 10 is a photograph showing the appearance of tumor-bearing mice with experimental group 2 high-affinity anti-tumor compound of CD169 provided by the present invention.
- Figure 11 is a photograph showing the appearance of a tumor-bearing mouse in a control group 2 orally in the same volume of a PBS solution containing natural sialic acid;
- Figure 12 is a comparison of tumor size taken from mice of Experimental Group 2 and Control 2;
- Figure 13 is a comparative analysis of tumor size data taken from mice of Experimental Group 2 and Control Group 2;
- Figure 14 is a graph showing the effect of the present invention on tumor metastasis in mice.
- Figure 15 is a graph showing the survival rate of mice in the study of toxicity in mice of the present invention.
- the invention provides a CD169 high affinity antitumor compound, the chemical formula of which is:
- the present invention provides a novel anti-tumor small molecule compound, 9-position benzopyran-thienyl N-acetylneuraminic acid monosaccharide (TCC-Neu5Ac), which is a CD169 high affinity antitumor compound provided by the present invention, Tumor killing can be performed using specific, broad-spectrum properties.
- TCC-Neu5Ac can target tumors in vivo and metabolize and grow on the surface of tumor cells to form TCC-Neu5Ac ligand. After recognition of macrophages near the tumor, they are phagocytized, and tumor fragments are released and presented to other immune cells, triggering an anti-tumor immune response.
- CD169 high affinity antitumor compound provided by the present invention is effective against various tumors and has an inhibitory effect on tumor metastasis.
- the CD169 high affinity antitumor compound provided by the invention can not only be injected, but also exerts oral action, and has low cytotoxicity and animal toxicity, and has excellent application prospect and value.
- the invention also provides a preparation method of CD169 high affinity antitumor compound, comprising the following preparation steps:
- 6-chloro-8-fluorochroman-4-one 1 (5 g, 24.9 mmol) was dissolved in 15 mL of dimethylformamide (N, N-Dimethylformamide, DMF for short) at 0 °C. , and phosphorus oxychloride (2.3 mL, 24.9 mmol) was added dropwise to obtain a mixture M51;
- sialic acid (15.0 g, 50 mmol), 1 ml of trifluoroacetic acid and 300 ml of anhydrous methanol was stirred at room temperature until clarification to obtain a mixture M41; wherein the chemical structure of the sialic acid expressed herein is as follows:
- the chemical synthesis route of the CD169 high affinity antitumor compound provided by the present invention is as follows:
- the invention also provides the use of a CD169 high affinity anti-tumor compound as described above.
- the CD169 high affinity antitumor compound provided by the present invention can achieve an antitumor effect by injection or oral administration.
- the human malignant glioma cells (U87) were cultured normally in a 37-degree constant temperature incubator containing 5% carbon dioxide, and the medium used was DMEM medium containing 10% fetal calf serum;
- the cells were passaged to a confocal dedicated cell culture dish and cultured to a density of 50%;
- the original medium was removed, and a medium containing TCC-Neu5Ac at a concentration of 100 ⁇ mol (100 uM) was added, and the culture was continued for 24 hours;
- the medium containing TCC-Neu5Ac was removed, carefully washed three times with PBS, new medium was added, and the distribution of TCC-Neu5Ac in the cells was observed by laser confocal microscopy.
- the excitation light used was 405 nm, and the emitted light in the range of 420-480 nm was intercepted, and the scale was 5 ⁇ m.
- FIG. 1 shows the distribution of TCC-Neu5Ac.
- mice-derived melanoma cells (B16F10) were cultured normally in a 37-degree constant temperature incubator containing 5% carbon dioxide, and the medium used was DMEM medium containing 10% fetal calf serum;
- the cells were passaged to a confocal dedicated cell culture dish and cultured to a density of 50%;
- the original medium was removed, and a medium containing TCC-Neu5Ac at a concentration of 100 ⁇ mol (100 uM) was added, and the culture was continued for 24 hours;
- the medium containing TCC-Neu5Ac was removed, carefully washed three times with PBS, new medium was added, and the distribution of TCC-Neu5Ac in the cells was observed by laser confocal microscopy.
- the excitation light used was 405 nm, and the emitted light in the range of 420-480 nm was intercepted, and the scale was 5 ⁇ m.
- FIG. 2 shows the distribution of TCC-Neu5Ac.
- the human malignant glioma cells (U87) were cultured normally in a 37-degree constant temperature incubator containing 5% carbon dioxide, and the medium used was DMEM medium containing 10% fetal calf serum;
- the cells were passaged to a confocal dedicated cell culture dish and cultured to a density of 50%.
- the original medium was removed, and a medium containing TCC-Neu5Ac at different concentrations from 0 to 100 micromolar (100 uM) was added, and the culture was continued for 24 hours;
- the medium containing TCC-Neu5Ac was removed, carefully washed three times with PBS, new medium was added, and the dead cells were counted in the placenta.
- the counting results are shown in Fig. 4, wherein the abscissa indicates the concentration of TCC-Neu5Ac added in the medium, and the ordinate indicates the cell survival rate. As shown in Fig. 4, different concentrations (0 to 100 micromoles) of TCC- are added to the medium. Neu5Ac, the survival rate of cells is not much different. It can be seen that the CD169 high affinity antitumor compound provided by the present invention has extremely low toxicity in cells, and it is feasible to be used as a human tumor treatment.
- the 10-week-old mouse bone marrow was taken out, and potassium chloride ammonium (ACK) lysate was added, and then the cells were cultured in an IMDM-containing medium containing 10% (volume ratio) fetal bovine serum (FBS), 10 ng/mL macrophage. Cell community stimulating factors, resulting in BMDM macrophages.
- the macrophages and B16F10 cells were incubated in the experimental group and the control medium at a ratio of 5:1.
- the experimental group was supplemented with TCC-Neu5Ac, and the control medium was supplemented with the same volume of Neu5Ac, using lactate dehydrogenase cells.
- the toxicity test kit is used for detection, and the SB nanometer absorption peak is selected by the microplate reader.
- the B16F10 cells were normally cultured in a 10 cm cell culture dish and cultured to a density of 80%;
- Control group 1 was injected with the same volume of PBS containing 100 micromoles of natural sialic acid, and the rest of the conditions were consistent with the experimental group.
- Fig. 8 After 15 days, the hair of the tumor site of the mouse was removed, photographed (as shown in Fig. 6 and Fig. 7), and the tumor of the mouse was taken out and photographed and analyzed. The results are shown in Fig. 8:
- Fig. 6 is a photograph showing the appearance of a tumor-bearing mouse in which the experimental group 1 was injected with the CD169 high affinity antitumor compound provided by the present invention
- Fig. 7 is a small tumor of the control group 1 injected with the same volume of PBS, containing 100 micromoles of natural sialic acid. Mouse appearance photo.
- the left side is the tumor taken out from the tumor group of the experimental group 1 in which the CD169 high affinity antitumor compound provided by the present invention is injected, and the tumor taken out in the control group 1 on the right side.
- the tumor-bearing mice injected with the CD169 high-affinity anti-tumor compound provided by the present invention have a tumor size significantly smaller than that of the same volume of PBS, and contain 100 micromoles of natural sialic acid (excluding the CD169 high-affinity anti-tumor compound provided by the present invention).
- B16F10 cells were cultured normally in 10 cm cell culture dishes, and cultured to 80% density; digested with 2 ml trypsin for 90 seconds, neutralized by adding 2 ml of medium, centrifuged at 300 g for 3 minutes, and centrifuged once more with PBS to remove residuals. The medium was resuspended in PBS and counted; 1 million prepared cells were injected subcutaneously into B6 strain mice (C57BL/6) for tumor implantation;
- the control group 2 was fed with an aqueous solution containing the same amount of natural sialic acid.
- Fig. 10 is a photograph showing the appearance of a tumor-bearing mouse having the CD169 high-affinity antitumor compound provided by the present invention in the experimental group 2;
- FIG. 11 is a control group 2 orally taking the same volume of PBS, containing 100 micromoles of natural sialic acid and having a small tumor.
- Mouse appearance photo In Fig. 12, the left side is a tumor taken from a tumor-bearing mouse having a CD169 high-affinity antitumor compound provided by the present invention orally, and the right side is a tumor taken out in a control 2 mouse.
- the above-mentioned tumor size was analyzed by data, and the data analysis chart was made as shown in FIG. 13; by comparing FIG. 10 and FIG. 11 and the tumor size comparison between the left and right sides in FIG. 12, compared with the analysis of FIG. It can be seen that the tumor size of tumor-bearing mice injected with the CD169 high-affinity anti-tumor compound provided by the present invention is significantly smaller than that of the same volume of PBS, containing 100 micromoles of natural sialic acid (excluding the CD169 high affinity resistance provided by the present invention). Tumor size of tumor mice with tumor compounds). Thus, it can be seen that the oral administration of the CD169 high affinity antitumor compound provided by the present invention has a remarkable effect against tumors.
- the B16F10 cells were normally cultured in a 10 cm cell culture dish and cultured to a density of 80%;
- One million prepared cells were injected from the tail vein into B6 strain mice (C57BL/6) for tumor metastasis model analysis. Thereafter, every two days, a volume of 100 ⁇ l of PBS containing 100 ⁇ mol of the present invention was injected from the tail vein of the mice as an experimental group.
- the control group was injected with the same volume of PBS containing 100 micromoles of natural sialic acid (Neu5Ac). After 15 days, the hair of the tumor site of the mouse was removed and photographed; the tumor of the mouse was taken out, and photographing and data analysis were performed.
- the experimental data analysis chart is shown in Fig. 14.
- the ordinate position of one of the black solid circles indicates the number of tumors transferred to the lungs in one experimental group; the ordinate position of one black solid square indicates the number of tumors transferred to the lungs in one control group. .
- the number of tumors transferred to the lungs of the experimental group was much lower than that of the control group, and it was found that the CD169 high affinity antitumor compound provided by the present invention has a remarkable effect of inhibiting tumor metastasis.
- B6 strain mice (C57BL/6) were injected from the tail vein every 5 days to a volume of 100 microliters containing 100 micromolar concentrations of PBS of the present invention.
- the control group was injected with natural sialic acid molecules containing the same volume concentration. Mice were observed and recorded.
- the experiment is seen in Figure 15.
- the abscissa of Fig. 15 represents the culture time of the mouse, and the ordinate represents the survival rate of the mouse.
- the survival rate of the mice of the experimental group and the control group did not differ much after 100 days of culture, and the CD169 provided by the present invention can be seen.
- High-affinity anti-tumor compounds are very toxic to mice and are useful as a treatment for human tumors.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (8)
- 根据权利要求1所述的一种CD169高亲和力抗肿瘤化合物的制备方法,其特征在于,包括以下制备步骤:步骤一、将 TCCSia methyl ester、甲醇和NaOH溶液混合,并在室温下搅拌一段时间得到混合物M11;步骤二、在步骤一得到的混合物M11中,加入HCl水溶液,调节混合物M11的pH为7,得到混合物M12;步骤三、将步骤二得到的混合物M12去除溶剂,将去除溶剂后的残余物进行纯化,制得固体即为CD169高亲和力抗肿瘤化合物。
- 根据权利要求2所述的一种CD169高亲和力抗肿瘤化合物的制备方法,其特征在于:步骤三中,将去除溶剂后的残余物通过柱层析进行纯化,所述柱层析中采用的CH 2Cl 2:MeOH=2:1。
- 根据权利要求2所述的一种CD169高亲和力抗肿瘤化合物的制备方法,其特征在于,步骤一中所述 TCCSia methyl ester的制备方法包括以下步骤:S110、将 N3Sia methyl ester、Pd/C催化剂和无水甲醇混合,得到混合物M21;S120、在S110得到的混合物M21中加入乙酰氯,调节pH为1~2,得到混合物M22;S130、将S120得到的混合物M22置于H 2中搅拌,并通过薄层色谱监测至反应完全,得到混合物M23;S140、将S130得到的混合物M23通过过滤,除去Pd/C催化剂,并采用蒸发去除溶剂,得到残留混合物M24;S150、将S140中得到的混合物M24、1-乙基-(3-二甲基氨基丙基)碳酰二亚胺盐 酸盐、1-羟基苯并三唑、三乙胺、TCC-COOH和二甲基甲酰胺混合,并在黑暗中搅拌一段时间,得到混合物M25;S160、将S150中得到的混合物M25蒸发除去溶剂,并将去除溶剂后的残余物通过柱层析进行纯化,得到固体即为 TCCSia methyl ester;其中,S160中,柱层析中采用的CH 2Cl 2:MeOH=10:1。
- 根据权利要求4所述的一种CD169高亲和力抗肿瘤化合物的制备方法,其特征在于,所述 N3Sia methyl ester的制备方法为:S210、将叠氮化钠和 TosSia methyl ester加入二甲基甲酰胺中得到混合物M31;S220、将S210中得到的混合物M31加热至80℃一段时间后,除去溶剂;S230、将S220去除溶剂后的残余物通过柱层析纯化,得到固体即为 N3Sia methyl ester;其中,S230中柱层析中采用的EtOAc:MeOH=20:1。
- 根据权利要求5所述的一种CD169高亲和力抗肿瘤化合物的制备方法,其特征在于,所述 TosSia methyl ester的制备方法为:S310、将唾液酸、三氟乙酸和无水甲醇混合后在室温下搅拌至澄清,得到混合物M41;S320、将S310中得到的混合物M41采用蒸发的方式除去溶剂,得到固体唾液酸甲酯;S330、将S320中得到的固体唾液酸甲酯和P 2O 5在真空干燥一段时间,得到混合物M42;S340、在S330中得到的混合物M42与无水吡啶共蒸发以除去水分,得到混合物M43;S350、将S340得到的混合物M43溶于无水吡啶中后,冷却至0℃,并加入对甲苯磺酰氯,得到混合物M44;S360、将S350中得到的混合物M44加热至室温并搅拌一段时间后,通过减压加热除去溶剂;S370、将S360除去溶剂后的残余物通过柱层析纯化,得到白色固体即为 TosSia methyl ester;其中,S370中柱层析所采用的EtOAc:MeOH=20:1。
- 根据权利要求4所述的一种CD169高亲和力抗肿瘤化合物的制备方法,其特征在于,所述TCC-COOH的合成方法为:S410、在0℃下,将6-氯-8-氟苯并二氢吡喃-4-酮1溶解于二甲基甲酰胺中,并逐滴加入磷酰氯,得到混合物M51;S420、将S410得到的混合物M51在0℃下搅拌30分钟后加热至80℃,保温1.5小时后冷却至室温,得到混合物M52;S430、将S420得到的混合物M52冷却至室温后,加入1N NaOAc溶液淬灭后,加入二氯甲烷进行萃取,将萃取后的有机层进行真空浓缩,得到4,6-二氯-8-氟-2H-色烯-3-甲醛;S440、在0℃下,于圆底烧瓶中,将S430得到的4,6-二氯-8-氟-2H-色烯-3-甲醛溶解在乙醇溶液中,逐滴加入的巯基乙酸乙酯与乙醇钠于溶液中,得到混合物M53;S450、将S440得到的混合物M53升温至室温并搅拌过夜后,进行过滤,得到沉淀物后,用水洗涤并收集沉淀物;S460、将S450得到的沉淀物加入四氢呋喃和1N NaOH溶液中,并在50℃下搅拌24小时,得到混合物M54;S470、将S460得到的混合物M54冷却至室温,用CH 2Cl 2洗涤,并加入1N HCl酸化,将所得固体产物过滤,用水洗涤并干燥,即得到TCC-COOH。
- 如权利要求1所述的CD169高亲和力抗肿瘤化合物,在治疗肿瘤方面的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/847,770 US11433087B2 (en) | 2017-10-14 | 2020-04-14 | Anti-tumor compound with high CD169 affinity, method thereof, and use thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710955544.7 | 2017-10-14 | ||
CN201710955544.7A CN107501291B (zh) | 2017-10-14 | 2017-10-14 | 一种cd169高亲和力抗肿瘤化合物及其制备方法和应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/847,770 Continuation US11433087B2 (en) | 2017-10-14 | 2020-04-14 | Anti-tumor compound with high CD169 affinity, method thereof, and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019072045A1 true WO2019072045A1 (zh) | 2019-04-18 |
Family
ID=60701688
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2018/103238 WO2019072045A1 (zh) | 2017-10-14 | 2018-08-30 | 一种cd169高亲和力抗肿瘤化合物及其制备方法和应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11433087B2 (zh) |
CN (1) | CN107501291B (zh) |
WO (1) | WO2019072045A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116063372A (zh) * | 2023-01-17 | 2023-05-05 | 齐齐哈尔医学院 | 一类线粒体靶向的抗肿瘤化合物及其制备方法和应用 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107501291B (zh) | 2017-10-14 | 2020-01-21 | 厦门诺康得生物科技有限公司 | 一种cd169高亲和力抗肿瘤化合物及其制备方法和应用 |
CN108218929A (zh) * | 2017-12-26 | 2018-06-29 | 厦门大学 | 一种c-9缀合唾液酸及其应用 |
CN108299472B (zh) * | 2018-01-16 | 2019-08-27 | 厦门诺康得生物科技有限公司 | 一种基于氨基唾液酸糖的cd169亲和荧光探针tcc-fitc及其制备方法 |
CN110041381A (zh) * | 2018-01-16 | 2019-07-23 | 厦门诺康得生物科技有限公司 | 一种cd169亲和三糖化合物及其制备方法 |
CN108191801B (zh) * | 2018-01-16 | 2020-12-22 | 厦门诺康得生物科技有限公司 | 一种基于氨基唾液酸糖的cd169亲和抗肿瘤化合物及其制备方法 |
CN110128490B (zh) * | 2018-02-09 | 2021-03-16 | 厦门诺康得生物科技有限公司 | 一种用于免疫细胞表面修饰的糖类衍生物及其应用 |
CN108676044B (zh) * | 2018-05-16 | 2021-03-30 | 厦门诺康得生物科技有限公司 | 一种cd33亲和的唾液酸衍生物及其应用 |
CN113694062A (zh) * | 2021-08-05 | 2021-11-26 | 深圳大学 | 一种含吡啶的化合物的抗肿瘤用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107501291A (zh) * | 2017-10-14 | 2017-12-22 | 厦门诺康得生物科技有限公司 | 一种cd169高亲和力抗肿瘤化合物及其制备方法和应用 |
CN107998140A (zh) * | 2017-11-13 | 2018-05-08 | 厦门诺康得生物科技有限公司 | 化合物r1的用途 |
CN108047282A (zh) * | 2017-12-19 | 2018-05-18 | 厦门诺康得生物科技有限公司 | 一种唾液酸衍生物及其制备方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004534085A (ja) * | 2001-06-19 | 2004-11-11 | ソージ ケルム | シグレック阻害剤 |
CN103819515B (zh) * | 2014-02-27 | 2016-03-09 | 厦门生光生物科技有限公司 | 一种荧光素标记的唾液酸试剂及其制备方法与应用 |
CN105017340B (zh) * | 2015-08-05 | 2017-11-14 | 厦门大学 | 一种抗原连接的唾液酸及其应用 |
-
2017
- 2017-10-14 CN CN201710955544.7A patent/CN107501291B/zh active Active
-
2018
- 2018-08-30 WO PCT/CN2018/103238 patent/WO2019072045A1/zh active Application Filing
-
2020
- 2020-04-14 US US16/847,770 patent/US11433087B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107501291A (zh) * | 2017-10-14 | 2017-12-22 | 厦门诺康得生物科技有限公司 | 一种cd169高亲和力抗肿瘤化合物及其制备方法和应用 |
CN107998140A (zh) * | 2017-11-13 | 2018-05-08 | 厦门诺康得生物科技有限公司 | 化合物r1的用途 |
CN108047282A (zh) * | 2017-12-19 | 2018-05-18 | 厦门诺康得生物科技有限公司 | 一种唾液酸衍生物及其制备方法和应用 |
Non-Patent Citations (3)
Title |
---|
KAWASAKI, N. ET AL.: "Targeted Delivery of Lipid Antigen to Macrophages via the CD 169/ Sialoadhesin Endocytic Pathway Induces Robust Invariant Natural Killer T Cell Activation", PNAS, vol. 110, no. 19, 7 May 2013 (2013-05-07), XP002719293, ISSN: 1091-6490, DOI: doi:10.1073/pnas.1219888110 * |
NYCHOLAT, C.M. ET AL.: "In Silico Aided Design of a Glycan Ligand of Sialoadhesin for in Vivo Targeting of Macrophages", J. AM. CHEM. SOC., vol. 134, no. 38, 26 September 2012 (2012-09-26), pages 15696 - 15699, XP055592174, ISSN: 0002-7863 * |
PENG, WENJIE ET AL.: "CD 22 Ligands on a Natural N-Glycan Scaffold Efficiently Deliver Toxins to B-Lymphoma Cells", J. AM. CHEM. SOC., vol. 139, no. 36, 13 September 2017 (2017-09-13), pages 12450 - 12458, XP055592171, ISSN: 0002-7863 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116063372A (zh) * | 2023-01-17 | 2023-05-05 | 齐齐哈尔医学院 | 一类线粒体靶向的抗肿瘤化合物及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN107501291B (zh) | 2020-01-21 |
CN107501291A (zh) | 2017-12-22 |
US11433087B2 (en) | 2022-09-06 |
US20200237797A1 (en) | 2020-07-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019072045A1 (zh) | 一种cd169高亲和力抗肿瘤化合物及其制备方法和应用 | |
US8921328B2 (en) | E-selectin antagonists | |
US10221155B2 (en) | Method for preparing Alectinib | |
CN108047282B (zh) | 一种唾液酸衍生物及其制备方法和应用 | |
JP2021512161A (ja) | Cdk4およびcdk6阻害剤としての2h−インダゾール誘導体およびその治療上の使用 | |
US11033562B2 (en) | Carbohydrate derivatives used for surface modification of immune cells, use thereof and method thereof | |
UA116534C2 (uk) | Піразолопіримідинілові інгібітори убіквітинактивуючого ферменту | |
PT98943B (pt) | Processo para a preparacao de novos analogos carbociclicos de adenosina e de composicoes farmaceuticas que os contem. | |
WO2014109256A1 (ja) | トリアゾール連結型環状ジヌクレオチド類縁体 | |
CN117157081A (zh) | 一种具有抗肿瘤活性的核苷酸衍生物及其药物组合物和用途 | |
CN112876463B (zh) | 一种制备pd-l1拮抗剂的中间体及其制备方法 | |
CN110548151B (zh) | 一种共价药物的设计方法 | |
KR101138438B1 (ko) | 스피루리나로부터 클로로필 a 및 광민감제 제조방법 | |
CN109897036B (zh) | 三唑并吡啶类化合物及其制备方法和用途 | |
CN102952207B (zh) | 6-(1-甲基-β-咔啉-3-羧酸乙酰基)-6-脱氧-β-环糊精及其与阿霉素超分子包结配合物的制备和应用 | |
US20130274210A1 (en) | Dendrimers with a saccharide ending for anti-inflammatory purposes | |
CN1686102A (zh) | 斑蝥素衍生物在制备抗肿瘤药物中的应用 | |
KR101106756B1 (ko) | 스피루리나로부터 클로로필 a 및 광민감제 제조방법 | |
CN102603824A (zh) | 具有抗癌活性的3’-叠氮基柔红霉素-13-缩氨基(硫)脲类新化合物和制备方法 | |
RU2642426C1 (ru) | 1-Этил-6-фтор-4-оксо-7-(8-этокси-2-оксо-2Н-хромен-3-ил)-1,4-дигидрохинолин-3-карбоновая кислота, обладающая противотуберкулезной активностью | |
WO2019233366A1 (zh) | 选择性a 2a受体拮抗剂 | |
KR101138437B1 (ko) | 스피루리나로부터 클로로필 a 및 광민감제 제조방법 | |
KR101332319B1 (ko) | 스피루리나로부터 클로로필 a 및 광민감제 제조방법 | |
CN113527153B (zh) | 一类抑制肠道炎症反应的活性化合物 | |
CN110963956B (zh) | 一种苯丙胺类新生物碱的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18865902 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18865902 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18865902 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 25-01-2021) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18865902 Country of ref document: EP Kind code of ref document: A1 |